Inspire Medical Systems, Inc. Announces Additional Draft Local Coverage Determinations Proposing Coverage of Inspire Therapy

Download as PDF

National Government Services and CGS Administrators, collectively representing 12 states, issue draft
policies initiating open public comment period

MINNEAPOLIS, MN – September 26, 2019 – Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a
medical technology company focused on the development and commercialization of innovative and
minimally invasive solutions for patients with obstructive sleep apnea, announced today that two
additional draft Local Coverage Determinations (“LCDs”) were published proposing coverage of Inspire

The Medicare Administrative Contractors (“MACs”) issuing these two policies are National Government
Services, Inc. (“NGS”) and CGS Administrators, LLC (“CGS”), which collectively represent 12 states. The
two additional draft LCDs are available on the Medicare Coverage Database site for public review. The
NGS public comment period runs from September 26, 2019 to November 9, 2019, and the CGS public
comment period runs from October 30, 2019 to December 14, 2019. NGS and CGS will host formal
review meetings during this process. The final LCDs are expected to be published in early 2020. Four
other MACs, Noridian, Palmetto, Novitas Solutions, and First Coast Service Options, previously published
their draft coverage policies. In total, these six MACs represent Medicare patients in 44 states and the
District of Columbia.

The draft LCDs from NGS and CGS are consistent with the previous publication of proposed LCDs from
Noridian, Palmetto, Novitas Solutions and First Coast Service Options, which state that for individuals
with obstructive sleep apnea who are treated with hypoglossal nerve stimulation, the evidence is sufficient
to determine that the technology results in a meaningful improvement in the net health outcomes when
utilized as outlined in the LCDs. The criteria for potential patients identified in the draft policy are closely
aligned with the approved U.S. Food and Drug Administration indication statement for Inspire therapy.

“With these two additional LCDs, Medicare patients in 44 states are expected to have access to Inspire
therapy. We look forward to the potential issuance of formal policies from NGS and CGS, and anticipate
that the one remaining MAC will also soon issue a draft policy for Inspire therapy,” said Tim Herbert,
President and Chief Executive Officer of Inspire Medical Systems.

NGS covers Medicare patients in Connecticut, Illinois, Maine, Massachusetts, Minnesota, New
Hampshire, New York, Rhode Island, Vermont, and Wisconsin. CGS covers Medicare patients in
Kentucky and Ohio.

One remaining MAC, Wisconsin Physicians Service Government Health Administrators, which covers
Medicare patients in Indiana, Iowa, Kansas, Michigan, Missouri, and Nebraska, has yet to publish a draft
LCD proposing coverage of Inspire therapy.

About Inspire Medical Systems

Inspire is a medical technology company focused on the development and commercialization of
innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary
Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and
effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding future local coverage determinations and additional draft policies for Inspire therapy. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, estimates regarding the annual total addressable market for our Inspire therapy in the U.S. and our market opportunity outside the U.S.; future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; commercial success and market acceptance of our Inspire therapy; our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize; competitive companies and technologies in our industry; our ability to enhance our Inspire system, expand our indications and develop and commercialize additional products; our business model and strategic plans for our products, technologies and business, including our implementation thereof; our ability to accurately forecast customer demand for our Inspire system and manage our inventory; our dependence on third-party suppliers, contract manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand, manage and maintain our direct sales and marketing organization, and to market and sell our Inspire system in markets outside of the U.S.; risks associated with international operations; our ability to manage our growth; our ability to increase the number of active medical centers implanting Inspire therapy; our ability to hire and retain our senior management and other highly qualified personnel; risk of product liability claims; risks related to information technology and cybersecurity; risk of damage to or interruptions at our facilities; our ability to commercialize or obtain regulatory approvals for our Inspire therapy and system, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the U.S. and international markets; the timing or likelihood of regulatory filings and approvals; risks related to our debt and capital structure; our ability to establish and maintain intellectual property protection for our Inspire therapy and system or avoid claims of infringement; tax risks; risks that we may be deemed an investment company under the Investment Company Act of 1940; regulatory risks; the volatility of the trading price of our common stock; and our expectations about market trends. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this presentation can be found under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations“ in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management’s estimates as of the date of this presentation. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
[email protected]